Compare National Beverage Corp. (FIZZ) vs Novo Nordisk A/S (NVO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
National Beverage Corp. vs Novo Nordisk A/S — how do they compare? National Beverage Corp. trades at $30.88 (market cap $2.77B), while Novo Nordisk A/S trades at $37.99 (market cap $168.73B). The key difference: Novo Nordisk A/S is far larger — about 60.9× National Beverage Corp.'s market cap, and Novo Nordisk A/S pays a 4.7% dividend while National Beverage Corp. pays none. Which is the better fit depends on your goals — on Pluang, investors hold National Beverage Corp. for 33 Days and Novo Nordisk A/S for 116 Days on average.
| FIZZ | NVO | |
|---|---|---|
Market Cap | $2.77B | $168.73B |
Volume | 413,496 | 13,531,267 |
Sector | Consumer Staples | Health |
52-Week High | $37.73 | $63.98 |
52-Week Low | $29.20 | $35.29 |
Typical Hold Time | 33 Days | 116 Days |
Enterprise Value | $2.72B | $183.05B |
Dividend Yield | — | 4.7% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FIZZ trades at $29.60, down 1.4% with bearish technical signals from moving averages. The company reported flat revenue of $1.2B in 2025 but maintained strong profitability with 36.2% gross margins and 40.1% ROE. Recent Q1 2027 results showed the first year-over-year revenue growth since Q1 2026, though margins compressed to 35% and EPS declined to $0.50. Analyst sentiment is cautious with 50% sell ratings amid concerns about stalled growth and margin pressure from input costs.
The outlook remains challenging with LaCroix volumes declining for four consecutive years and Trump tariffs impacting profitability. While valuation multiples appear reasonable (P/E 15.9, EV/EBITDA 11.3), the lack of clear growth catalysts and negative cash flow trends present headwinds. The $3.25 special dividend provides shareholder return but reduces equity base, highlighting the company's mature market position.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →
